Ariel Jones

Cancer Nursing Today nonprod

A phase II study of single-agent nivolumab in patients with myelofibrosis was terminated early, after failing to meet its primary efficacy endpoint. Iman Abou Dalle, MD, from The University of Texas MD Anderson Cancer Center, and coauthors published these findings in the Annals of Hematology.&ldquo;Dysregulated JAK-STAT signaling in myelofibrosis induces pro-inflammatory cytokines, which suppresses T cell proliferation and differentiation, likely responsible for disease progression,&rdquo; the authors explained. &ldquo;The PD-1 pathway, found to be overexpressed in myeloid malignancies, has gained great interest as a therapeutic target, where a significant unmet need exists for novel therapeutic strategies.&rdquo;Based on findings from preclinical models which showed that JAK2 mutant cells had higher expression of PD-L1, investigators evaluated the efficacy and safety of single-agent nivolumab in eight adult patients with myelofibrosis.Patients received nivolumab 3 mg/kg every two weeks for eight doses, then every 12 weeks for up to four years, or until disease progression or toxicity.The median number of nivolumab doses received was six (range, 5-16). Five patients had stable disease including spleen size, total symptom score, and blood requirements, for a median of 3.3 months (range, 2.3-15.2 months).After a median follow-up of 57 months, two patients were still alive, with a median overall survival of 6.1 months (range, 3.2-57.4 months). &ldquo;Due to failure to meet the predetermined efficacy endpoint, the study was terminated early,&rdquo; the authors concluded.

Evaluating Single-Agent Nivolumab in Patients With Myelofibrosis

Myelofibrosis

A phase II study of single-agent nivolumab in patients with myelofibrosis was terminated early, after failing to meet its primary efficacy endpoint. Iman Abou Dalle, MD, from The University of Texas MD Anderson Cancer Center, and coauthors published these findings in the Annals of Hematology. “Dysregulated JAK-STAT signaling in myelofibrosis induces pro-inflammatory cytokines, which suppresses [...]

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe